Clinical characteristics and outcomes of <i>BRCA</i>-associated ovarian cancer (OC): Genotype and survival.

Engelstaedter, Verena; Cristea, Mihaela; Garber, Judy E.; Neuhausen, Susan L.; Frankel, Paul; Sand, Sharon; Steele, Linda; Matulonis, Ursula A.; Liu, J.; Weitzel, Jeffrey N.

doi:10.1200/jco.2010.28.15_suppl.5017

Cited by 1 publication

(1 citation statement)

References 39 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cells defective in the distal part of the pathway, namely in homologous recombination, are hypersensitive to ICL agents, etoposide and irradiation (Hucl et al 2008). Increased sensitivity to some of these drugs may be responsible for better survival of FA-deficient tumors (Engelstaedter et al 2010).…”

Section: Targeting Dna Repair Defects In Cancermentioning

confidence: 99%

DNA Repair: Exploiting the Fanconi Anemia Pathway As a Potential Therapeutic Target

Hucl

Gallmeier²

2011

Physiol Res

View full text Add to dashboard Cite

DNA repair is an active cellular process to respond to constant DNA damage caused by metabolic processes and environmental factors. Since the outcome of DNA damage is generally adverse and long term effects may contribute to oncogenesis, cells have developed a variety of DNA repair mechanisms, which operate depending on the type of DNA damage inflicted. At least 15 Fanconi anemia (FA) proteins interact in a common pathway involved in homologous recombination. Inherited homozygous mutations in any of these FA genes cause a rare disease, Fanconi anemia, characterized by congenital abnormalities, progressive bone-marrow failure and cancer susceptibility. Heterozygous germline FA mutations predispose to various types of cancer. In addition, somatic FA mutations have been identified in diverse cancer types. Evidence exists that cells deficient in the FA pathway become dependent on alternative pathways for survival. Additional inhibition of such alternative pathways is thus expected to result in cell death, creating a relationship of synthetic lethality. Identifying these relationships can reveal yet unknown mechanisms of DNA repair and new targets for therapy.

show abstract

Section: Targeting Dna Repair Defects In Cancermentioning

confidence: 99%

DNA Repair: Exploiting the Fanconi Anemia Pathway As a Potential Therapeutic Target

Hucl

Gallmeier²

2011

Physiol Res

View full text Add to dashboard Cite

show abstract

Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): Genotype and survival.

Abstract: Background-Prior studies have suggested that BRCA-related epithelial ovarian cancer (EOC) conveys improved survival compared to sporadic EOC, but few studies have studied differences between BRCA genotypes. We compared characteristics and outcome by genotype in BRCAassociated EOC.

Cited by 1 publication

References 39 publications

DNA Repair: Exploiting the Fanconi Anemia Pathway As a Potential Therapeutic Target

DNA Repair: Exploiting the Fanconi Anemia Pathway As a Potential Therapeutic Target

Contact Info

Product

Resources

About